Gelonghui February 1st 丨Eling Pharmaceutical (002603.SZ) announced that net profit attributable to shareholders of listed companies in 2022 is expected to be 2,150 billion yuan - 2,419 billion yuan, an increase of 60%-80% over the previous year; net profit after deducting non-recurring profit and loss is 2,024 billion yuan - 2,340 billion yuan, an increase of 60%-85% over the previous year;Mainly, during the reporting period, the sales revenue of the company's leading products increased by a certain margin compared to the same period last year.